Paediatric research should take centre stage

August 26, 2004

An editorial in this week's issue of THE LANCET comments on the recent UK Government's announcement of a new initiative to encourage the development of more medicines designed specifically for use in children. "Off-label" use is common in paediatrics, which can mean that drugs have not been tested at all in children or in a particular age group, or are given by an unlicensed route, for an unlicensed indication, or at an unlicensed dose. As Patrina Caldwell and colleagues explain in a review article in this week's issue (p 803), doing clinical trials in children is difficult for many reasons and requires specific expertise and extraordinary commitment by all those involved. The editorial comments: 'With drug companies generally uninterested because of low market value and with harsh competition from adult studies for funding by the public or charity sector, research grants for clinical trials in children are very hard to come by. So any special attention to, and encouragement for, paediatric research is very welcome.'

The absence of a legal obligation on companies to produce information on drug trials among children is seen as a weakness of the new proposal: 'Without legislation, companies will not voluntarily undertake paediatric trials because they are politely encouraged to do so'.

The editorial concludes: 'Another part of the UK Government's initiative is the investment of part of additional £100 million announced in April, 2004, into a new research network on medicines in children. In addition to medicines in children, research networks will initially cover cancer, mental health, diabetes, stroke, and Alzheimer's disease. An effective research network for paediatric trials with a wider remit, rather than just for medicines in children, would be an extremely valuable step forward in an area where data are lacking and disease prevention, diagnosis, treatment, and care are all too often based on no more then anecdotal evidence. As presented, this new initiative falls a long way short of what children deserve: centre stage for acquiring research-based evidence.'
ISSUE: 28 August-3 September 2004


Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to